Experimental Ebola Drug Shows Promise In Treating Early Infection, Study Shows

Agence France-Presse: Limited promise in early results from Ebola drug trial
“Early results from an Ebola trial using the experimental drug Avigan (favipiravir) showed it was somewhat effective at saving lives if given early in the illness, but not later…” (2/23).

Reuters: Ebola drug in Guinea helps some, stirs debate on broader use
“…Alliance for International Medical Action (ALIMA), which ran the trials of favipiravir in Guinea, said mortality rates fell from 30 to 15 percent in patients with a low to moderate Ebola count but was not effective on those with a high level of the virus…” (Farge, 2/23).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KFF | twitter.com/kff

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.